[Mucous membrane pemphigoid with ocular involvement. Part II: therapy].
Treatment of mucous membrane pemphigoid (MMP) aims at reduction of conjunctival inflammation by means of systemic immunosuppression. In addition, cicatricial progression and management of the resulting ocular surface disease requires topical conservative or surgical measures. The former includes systemic immunosuppression with steroids and other immunosuppressive agents: dapsone in mild to moderate disease and cyclophosphamide in severe cases have been established in two randomized trials. Other agents such as methotrexate, azathioprine, mycophenolate mofetil or monoclonal antibodies including daclizumab or rituximab were found to be effective in uncontrolled small studies. Surgery is primarily focused on eyelid problems such as entropium and trichiasis. Ocular surface disease and secondary complications, e.g. cataract formation and glaucoma, may need surgical treatment. Any surgery is associated with the risk of a relapse of inflammation and should be postponed until inflammation is controlled by systemic therapy. Management of MMP patients requires close collaboration of a specialized ophthalmologist with specialists from dermatology and internal medicine.
Meyer-ter-Vehn
T
T
Klinik für Augenheilkunde, Julius-Maximilians-Universität Würzburg, Josef-Schneider-Strasse 11, 97080 Würzburg, Deutschland.
Schmidt
E
E
Zillikens
D
D
Geerling
G
G
D003231:Conjunctivitis / Q000628:therapy*; D003316:Corneal Diseases / Q000628:therapy*; D005141:Eyelid Diseases / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D013508:Ophthalmologic Surgical Procedures / Q000379:methods*; D010390:Pemphigoid, Benign Mucous Membrane / Q000628:therapy*
D007166:Immunosuppressive Agents